Efficacy, effectiveness and real life goal attainment of statins in managing cardiovascular risk

References

• OhsfeldtRLGandhiSKFoxKMStacyTAMcKenneyJMEffectiveness and cost-effectiveness of rosuvastatin, atorvastatin, and simvastatin among high-risk patients in usual clinical practiceAm J Manag Care200612S412S42317112329
   PubMed Web of Science ®Google Scholar
• WardSLloyd JonesMPandorAA systematic review and economic evaluation of statins for the prevention of coronary eventsHealth Technol Assess2007111160iiiiv
   Web of Science ®Google Scholar
• LewingtonSWhitlockGClarkeRBlood cholesterol and vascular mortality by age, sex, and blood pressure: a meta-analysis of individual data from 61 prospective studies with 55,000 vascular deathsLancet20073701829183918061058
   PubMed Web of Science ®Google Scholar
• CannonCPBraunwaldEMcCabeCHIntensive versus moderate lipid lowering with statins after acute coronary syndromesN Engl J Med20043501495150415007110
   PubMed Web of Science ®Google Scholar
• LaRosaJCGrundySMWatersDDIntensive lipid lowering with atorvastatin in patients with stable coronary diseaseN Engl J Med20053521425143515755765
   PubMed Web of Science ®Google Scholar
• NissenSETuzcuEMSchoenhagenPEffect of intensive compared with moderate lipid-lowering therapy on progression of coronary atherosclerosis: a randomized controlled trialJAMA20042911071108014996776
   PubMed Web of Science ®Google Scholar
• GrundySMCleemanJIMerzCNImplications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III GuidelinesJ Am Coll Cardiol20044472073215358046
   PubMed Web of Science ®Google Scholar
• JonesPHDavidsonMHSteinEAComparison of the efficacy and safety of rosuvastatin versus atorvastatin, simvastatin, and pravastatin across doses (STELLAR* Trial)Am J Cardiol20039215216012860216
   PubMed Web of Science ®Google Scholar
• GrahamIAtarDBorch-JohnsenKEuropean guidelines on cardiovascular disease prevention in clinical practice: executive summaryAtherosclerosis200719414517880983
   PubMed Web of Science ®Google Scholar
• TobertJALovastatin and beyond: the history of the HMG-CoA reductase inhibitorsNat Rev Drug Discov2003251752612815379
   PubMed Web of Science ®Google Scholar
• Press ReleaseRecordati S.p.A: Obtains European Licence for Pitavastatin. 2008Accessed 02/21/2009;Available from http://biz.yahoo.com/iw/081024/0446144.html
   Google Scholar
• JacobsonTAStatin safety: lessons from new drug applications for marketed statinsAm J Cardiol20069744C51C16377282
   PubMed Web of Science ®Google Scholar
• Clinical implications of drug interactions with statin therapy- a guide to optimizing care and decreasing risk for adverse events. National Lipid Association, 2008 Accessed 01/05/2009;Available from http://www.lipid.org/clinical/insights/1000013.php
   Google Scholar
• ShitaraYSugiyamaYPharmacokinetic and pharmacodynamic alterations of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors: drug-drug interactions and interindividual differences in transporter and metabolic enzyme functionsPharmacol Ther20061127110516714062
   PubMed Web of Science ®Google Scholar
• LawMRWaldNJRudnickaARQuantifying effect of statins on low density lipoprotein cholesterol, ischaemic heart disease, and stroke: systematic review and meta-analysisBMJ2003326142312829554
   PubMed Web of Science ®Google Scholar
• ParkSKangHJRimSJA randomized, open-label study to evaluate the efficacy and safety of pitavastatin compared with simvastatin in Korean patients with hypercholesterolemiaClin Ther2005271074108216154486
   PubMed Web of Science ®Google Scholar
• SasakiJIkedaYKuribayashiTA 52-week, randomized, open-label, parallel-group comparison of the tolerability and effects of pitavastatin and atorvastatin on high-density lipoprotein cholesterol levels and glucose metabolism in Japanese patients with elevated levels of low-density lipoprotein cholesterol and glucose intoleranceClin Ther2008301089110118640465
   PubMed Web of Science ®Google Scholar
• Influence of pravastatin and plasma lipids on clinical events in the West of Scotland Coronary Prevention Study (WOSCOPS)Circulation199897144014459576423
   PubMed Web of Science ®Google Scholar
• MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trialLancet200236072212114036
   PubMed Web of Science ®Google Scholar
• ColhounHMBetteridgeDJDurringtonPNPrimary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trialLancet200436468569615325833
   PubMed Web of Science ®Google Scholar
• Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S)Lancet1994344138313897968073
   PubMed Web of Science ®Google Scholar
• SacksFMPfefferMAMoyeLAThe effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigatorsN Engl J Med1996335100110098801446
   PubMed Web of Science ®Google Scholar
• Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. The Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study GroupN Engl J Med1998339134913579841303
   PubMed Web of Science ®Google Scholar
• DownsJRClearfieldMWeisSPrimary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention StudyJAMA1998279161516229613910
   PubMed Web of Science ®Google Scholar
• SeverPSDahlofBPoulterNRPrevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial – Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trialLancet20033611149115812686036
   PubMed Web of Science ®Google Scholar
• RobinsonJGSmithBMaheshwariNSchrottHPleiotropic effects of statins: benefit beyond cholesterol reduction? A meta-regression analysisJ Am Coll Cardiol2005461855186216286171
   PubMed Web of Science ®Google Scholar
• LaRosaJCLow-density lipoprotein cholesterol reduction: the end is more important than the meansAm J Cardiol200710024024217631077
   PubMed Web of Science ®Google Scholar
• RobinsonJGWangSSmithBJJacobsonTAMeta-analysis of the relationship between non-high-density lipoprotein cholesterol reduction and coronary heart disease riskJ Am Coll Cardiol20095331632219161879
   PubMed Web of Science ®Google Scholar
• SchmidtWMSpielAOJilmaBWolztMMullerMIn-vivo effects of simvastatin and rosuvastatin on global gene expression in peripheral blood leucocytes in a human inflammation modelPharmacogenet Genomics20081810912018192897
   PubMed Web of Science ®Google Scholar
• ShiotaMKusakabeHHikitaYNakaoTIzumiYIwaoHPharmacogenomics of cardiovascular pharmacology: molecular network analysis in pleiotropic effects of statin – an experimental elucidation of the pharmacologic action from protein-protein interaction analysisJ Pharmacol Sci2008107151918490854
   PubMed Web of Science ®Google Scholar
• TangQOTranGTGamieZStatins: under investigation for increasing bone mineral density and augmenting fracture healingExpert Opin Investig Drugs20081714351463
   PubMed Web of Science ®Google Scholar
• Abou-RayaAAbou-RayaSHelmiiMStatins: potentially useful in therapy of systemic sclerosis-related Raynaud’s phenomenon and digital ulcersJ Rheumatol2008351801180818709692
   PubMed Web of Science ®Google Scholar
• ParaskevasKITzovarasAABrianaDDMikhailidisDPEmerging indications for statins: a pluripotent family of agents with several potential applicationsCurr Pharm Des2007133622363618220799
   PubMed Web of Science ®Google Scholar
• MillsEJRachlisBWuPDevereauxPJAroraPPerriDPrimary prevention of cardiovascular mortality and events with statin treatments: a network meta-analysis involving more than 65,000 patientsJ Am Coll Cardiol2008521769178119022156
   PubMed Web of Science ®Google Scholar
• RidkerPMDanielsonEFonsecaFARosuvastatin to prevent vascular events in men and women with elevated C-reactive proteinN Engl J Med20083592195220718997196
   PubMed Web of Science ®Google Scholar
• BaigentCKeechAKearneyPMEfficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statinsLancet20053661267127816214597
   PubMed Web of Science ®Google Scholar
• RidkerPMRifaiNClearfieldMMeasurement of C-reactive protein for the targeting of statin therapy in the primary prevention of acute coronary eventsN Engl J Med20013441959196511430324
   PubMed Web of Science ®Google Scholar
• KoshiyamaHTaniguchiATanakaKEffects of pitavastatin on lipid profiles and high-sensitivity CRP in Japanese subjects with hypercholesterolemia: Kansai Investigation of Statin for Hyperlipidemic Intervention in Metabolism and Endocrinology (KISHIMEN) investigatarsJ Atheroscler Thromb20081534535019075492
   PubMed Web of Science ®Google Scholar
• KinlaySLow-density lipoprotein-dependent and -independent effects of cholesterol-lowering therapies on C-reactive protein: a meta-analysisJ Am Coll Cardiol2007492003200917512355
   PubMed Web of Science ®Google Scholar
• RidkerPMPaynterNPRifaiNGazianoJMCookNRC-reactive protein and parental history improve global cardiovascular risk prediction: the Reynolds Risk Score for menCirculation2008118224322514p following 51.18997194
   PubMed Web of Science ®Google Scholar
• MayerCGruberHJLandlEMRosuvastatin reduces interleukin-6-induced expression of C-reactive protein in human hepatocytes in a STAT3- and C/EBP-dependent fashionInt J Clin Pharmacol Ther2007453192717595889
   PubMed Web of Science ®Google Scholar
• VoletiBAgrawalAStatins and nitric oxide reduce C-reactive protein production while inflammatory conditions persistMol Immunol20064389189616054696
   PubMed Web of Science ®Google Scholar
• ArnaudCBurgerFSteffensSStatins reduce interleukin-6-induced C-reactive protein in human hepatocytes: new evidence for direct antiinflammatory effects of statinsArterioscler Thromb Vasc Biol2005251231123615790934
   PubMed Web of Science ®Google Scholar
• AiMOtokozawaSAsztalosBFEffects of maximal doses of atorvastatin versus rosuvastatin on small dense low-density lipoprotein cholesterol levelsAm J Cardiol200810131531818237592
   PubMed Web of Science ®Google Scholar
• SuperkoHRGadesamRRIs it LDL particle size or number that correlates with risk for cardiovascular disease?Curr Atheroscler Rep200810537738518706278
   PubMed Web of Science ®Google Scholar
• BrunzellJDDavidsonMFurbergCDLipoprotein management in patients with cardiometabolic risk: consensus conference report from the American Diabetes Association and the American College of Cardiology FoundationJ Am Coll Cardiol2008511512152418402913
   PubMed Web of Science ®Google Scholar
• BrunzellJDDavidsonMFurbergCDLipoprotein management in patients with cardiometabolic risk: consensus statement from the American Diabetes Association and the American College of Cardiology FoundationDiabetes Care20083181182218375431
   PubMed Web of Science ®Google Scholar
• NissenSENichollsSJSipahiIEffect of very high-intensity statin therapy on regression of coronary atherosclerosis: the ASTEROID trialJAMA20062951556156516533939
   PubMed Web of Science ®Google Scholar
• TaylorAJKentSMFlahertyPJCoyleLCMarkwoodTTVernalisMNARBITER: Arterial Biology for the Investigation of the Treatment Effects of Reducing Cholesterol: a randomized trial comparing the effects of atorvastatin and pravastatin on carotid intima medial thicknessCirculation20021062055206012379573
   PubMed Web of Science ®Google Scholar
• CrouseJR3rdRaichlenJSRileyWAEffect of rosuvastatin on progression of carotid intima-media thickness in low-risk individuals with subclinical atherosclerosis: the METEOR TrialJAMA20072971344135317384434
   PubMed Web of Science ®Google Scholar
• RiesenWFNollGDarioloRImpact of enhanced compliance initiatives on the efficacy of rosuvastatin in reducing low density lipoprotein cholesterol levels in patients with primary hypercholesterolaemiaSwiss Med Wkly200813842042618654867
   PubMed Web of Science ®Google Scholar
• RiccioniGBazzanoLABucciarelliTManciniBdi IlioED’OrazioNRosuvastatin reduces intima-media thickness in hypercholesterolemic subjects with asymptomatic carotid artery disease: the Asymptomatic Carotid Atherosclerotic Disease in Manfredonia (ACADIM) StudyExpert Opin Pharmacother200892403240818778179
   PubMed Web of Science ®Google Scholar
• FlegJLMeteMHowardBVEffect of statins alone versus statins plus ezetimibe on carotid atherosclerosis in type 2 diabetes: the SANDS (Stop Atherosclerosis in Native Diabetics Study) trialJ Am Coll Cardiol2008522198220519095139
   PubMed Web of Science ®Google Scholar
• KasteleinJJde GrootESankatsingRAtherosclerosis measured by B-mode ultrasonography: effect of statin therapy on disease progressionAm J Med2004116Suppl 6A31S36S15050190
   PubMedGoogle Scholar
• KotsevaKStagmoMDe BacquerDDe BackerGWoodDTreatment potential for cholesterol management in patients with coronary heart disease in 15 European countries: findings from the EUROASPIRE II surveyAtherosclerosis200819771071717765905
   PubMed Web of Science ®Google Scholar
• Clinical reality of coronary prevention guidelines: a comparison of EUROASPIRE I and II in nine countries. EUROASPIRE I and II GroupEuropean Action on Secondary Prevention by Intervention to Reduce EventsLancet2001357995100111293642
   PubMedGoogle Scholar
• Van GanseELaforestLAlemaoEDaviesGGutkinSYinDLipid-modifying therapy and attainment of cholesterol goals in Europe: the Return on Expenditure Achieved for Lipid Therapy (REALITY) studyCurr Med Res Opin2005211389139916197657
   PubMed Web of Science ®Google Scholar
• DeambrosisPSaraminCTerrazzaniGEvaluation of the prescription and utilization patterns of statins in an Italian local health unit during the period 1994–2003Eur J Clin Pharmacol20076319720317200832
   PubMed Web of Science ®Google Scholar
• PerreaultSBlaisLLamarreDPersistence and determinants of statin therapy among middle-aged patients for primary and secondary preventionBr J Clin Pharmacol20055956457315842555
   PubMed Web of Science ®Google Scholar
• PedanAVarastehLSchneeweissSAnalysis of factors associated with statin adherence in a hierarchical model considering physician, pharmacy, patient, and prescription characteristicsJ Manag Care Pharm20071348749617672810
   PubMed Web of Science ®Google Scholar